Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALNY

Alnylam Pharmaceuticals Inc

Sep 06 • 04:00PM ET

246.78

Dollar change -4.70
Percentage change -1.87	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VO VXF VUG IBB XBI VOT IWP IWF VHT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.60	Insider Own	0.90%	Shs Outstand	128.38M	Perf Week	-14.02%
Market Cap	31.68B	Forward P/E	-	EPS next Y	-1.49	Insider Trans	-11.96%	Shs Float	127.22M	Perf Month	-5.15%
Income	-72.94M	PEG	-	EPS next Q	-0.91	Inst Own	93.94%	Short Float	3.55%	Perf Quarter	65.29%
Sales	2.34B	P/S	13.51	EPS this Y	31.13%	Inst Trans	0.93%	Short Ratio	3.71	Perf Half Y	64.67%
Book/sh	-0.02	P/B	-	EPS next Y	38.34%	ROA	-1.97%	Short Interest	4.52M	Perf Year	23.18%
Cash/sh	20.44	P/C	12.07	EPS next 5Y	-	ROE	-	52W Range	141.98 - 287.55	Perf YTD	28.93%
Dividend Est.	-	P/FCF	99.36	EPS past 5Y	14.18%	ROI	-2.80%	52W High	-14.18%	Beta	0.39
Dividend TTM	-	Quick Ratio	2.93	Sales past 5Y	97.61%	Gross Margin	87.00%	52W Low	73.82%	ATR (14)	10.06
Dividend Ex-Date	-	Current Ratio	3.01	EPS Y/Y TTM	93.35%	Oper. Margin	4.38%	RSI (14)	39.94	Volatility	3.77% 3.31%
Employees	2100	Debt/Eq	-	Sales Y/Y TTM	89.46%	Profit Margin	-3.11%	Recom	1.84	Target Price	289.65
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	93.98%	Payout	-	Rel Volume	0.56	Prev Close	251.48
Sales Surprise	47.54%	EPS Surprise	87.82%	Sales Q/Q	107.00%	Earnings	Aug 01 BMO	Avg Volume	1.22M	Price	246.78
SMA20	-8.50%	SMA50	-3.94%	SMA200	32.19%	Trades		Volume	682,405	Change	-1.87%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-16-24	Upgrade	Goldman	Neutral → Buy	$198 → $370
Feb-16-24	Downgrade	Goldman	Buy → Neutral	$173
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$171
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform	$208
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220
Mar-21-23	Initiated	Bernstein	Outperform	$243
Jan-18-23	Initiated	Canaccord Genuity	Buy	$310
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight	$222
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$175
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$210 → $178
Mar-01-22	Initiated	Citigroup	Buy	$223
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy	$170
Jan-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$181 → $208
Nov-22-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$144 → $225

Show Previous Ratings

Sep-06-24 07:09PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Aug-30-24 04:19PM	Why IBD 50's Alnylam Just Reversed Its 50% Gain And BridgeBio Surged (Investor's Business Daily) -8.47%
04:03PM	Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug (The Wall Street Journal)
02:33PM	ESC Congress: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam (Pharmaceutical Technology)
02:33PM	ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam (Pharmaceutical Technology)
10:13AM	Loading…
10:13AM	Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations (Investor's Business Daily)
06:00AM	Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran? in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress (Business Wire)
02:00AM	Full study data back Alnylam heart drugs benefit, but leave doctors with tough choices (BioPharma Dive)
Aug-28-24 04:00PM	Alnylam to Webcast Presentations at Upcoming September Investor Conferences (Business Wire)
Aug-23-24 10:22AM	Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition (Zacks)
Aug-21-24 02:45AM	Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q2 (Insider Monkey)
Aug-07-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in August 2024 (InvestorPlace)
08:00AM	Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024 (Business Wire)
Aug-04-24 06:55PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Aug-02-24 09:45AM	Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues (Zacks)
06:39AM	Loading…
06:39AM	Vir retreats from infectious disease; Vertex shelves AATD drugs (BioPharma Dive)
01:03AM	Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight (GuruFocus.com)
Aug-01-24 07:25PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +13.12%
11:30AM	Alnylam (ALNY) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
09:15AM	Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates (Zacks)
08:14AM	Alnylam: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity (Business Wire)
Jul-30-24 09:15AM	Seeking Clues to Alnylam (ALNY) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Jul-25-24 10:01AM	Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-18-24 08:00AM	Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results (Business Wire)
06:05AM	Alnylam Stock Is a Blockbuster Biopharma In the Making (InvestorPlace)
Jul-11-24 06:30AM	35% Surge Just the Beginning? Alnylam's Stock Poised for Massive Gains on Heart Drug Success. (InvestorPlace)
Jul-09-24 06:00AM	7 Cheap Biotech Stocks With Major Upside Potential (InvestorPlace)
Jul-08-24 04:52AM	Pipeline Moves: Alnylams Amvuttra approval prospects up after Phase III win (Clinical Trials Arena)
Jul-05-24 03:01PM	Baillie Gifford's Strategic Reduction in Alnylam Pharmaceuticals Holdings (GuruFocus.com)
07:45PM	Loading…
Jun-25-24 07:45PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +7.74%
08:59AM	Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals (Zacks)
Jun-24-24 09:41PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +34.52%
04:11PM	Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug (Investor's Business Daily)
01:54PM	Alnylam Soars on Positive Heart-Drug Data (The Wall Street Journal)
01:54PM	Successful heart drug trial prompts Alnylam stock to jump 35 percent (Quartz)
01:05PM	US Treasury Secretary Janet Yellen speaks to Yahoo Finance (Yahoo Finance Video)
12:52PM	RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024 (Associated Press Finance)
12:42PM	Alnylam reveals positive Phase III results for rare heart disease drug vutrisiran (Pharmaceutical Technology)
12:32PM	Tech sector growth, EU considers fining Apple: Morning Brief (Yahoo Finance Video)
10:53AM	Alnylam Stock Pops on Surprising Results From a Key Heart Disease Drug (Barrons.com)
10:52AM	Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears (InvestorPlace)
10:33AM	Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success (InvestorPlace)
10:25AM	Alnylam Stock Soars on Strong Results in Heart Drug Study (Investopedia)
10:24AM	Alnylam stock skyrockets on positive heart drug results (Yahoo Finance Video)
10:06AM	Alnylam Soars After Drug Meets Goal in Heart Disease Trial (Bloomberg)
08:51AM	Alnylam Stock Soars After Positive Results From Heart Disease Study (Barrons.com)
07:00AM	Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations (Business Wire)
06:49AM	Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
04:20AM	Alnylam says heart drug succeeds in closely watched study (BioPharma Dive)
04:20AM	Alnylam claims success in closely watched heart drug study (BioPharma Dive)
Jun-05-24 06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
May-07-24 09:12AM	HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating (MT Newswires)
08:00AM	Alnylam Issues 2023 Corporate Responsibility Report (Business Wire)
May-03-24 01:01PM	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:29PM	Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y (Zacks)
10:48AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
03:11AM	Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ... (GuruFocus.com)
01:06AM	Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight (GuruFocus.com)
May-02-24 12:53PM	ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:00AM	Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics (Zacks)
09:10AM	Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
09:04AM	Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed (MT Newswires)
08:08AM	Alnylam: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity (Business Wire)
May-01-24 08:10AM	Pfizers strong Vyndaqel sales draw attention to rare disease drugs patent life (BioPharma Dive)
Apr-30-24 09:15AM	Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics (Zacks)
07:00AM	Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia (PR Newswire)
Apr-29-24 09:49AM	5 Most Promising Stocks to Buy Before They Take Off (Insider Monkey)
Apr-25-24 10:01AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-18-24 08:00AM	Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results (Business Wire)
Apr-08-24 08:44AM	Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick (Zacks)
Apr-07-24 08:00AM	Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension (Business Wire)
Mar-20-24 08:00AM	Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session (Business Wire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-13-24 07:30AM	Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease (Business Wire)
Mar-06-24 11:26AM	Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal (Zacks)
Mar-05-24 09:06AM	ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category (PR Newswire)
08:27AM	Roche, Alnylam say blood pressure drug succeeds in mid-stage trial (Reuters)
07:52AM	Alnylam, Roche blood pressure drug scores in second mid-stage trial (BioPharma Dive)
07:30AM	Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives (Business Wire)
Feb-27-24 08:30AM	Alnylam to Webcast Presentations at Upcoming March Investor Conferences (Business Wire)
Feb-24-24 08:45AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Feb-21-24 12:06PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Feb-16-24 12:08PM	Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10% (Zacks)
09:46AM	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript (Insider Monkey)
01:55AM	Q4 2023 Alnylam Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
12:02AM	Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight (GuruFocus.com)
Feb-15-24 12:39PM	Why Alnylam Pharmaceuticals Stock Is Sinking Today (Motley Fool) -10.19%
10:30AM	Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:37AM	Alnylam Pharmaceuticals Inc (ALNY) Reports Strong Growth in 2023, Aiming for Continued Success ... (GuruFocus.com)
08:17AM	Alnylam: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity (Business Wire)
06:54AM	Alnylam changes to heart drug trial spark doubts, sinking shares (BioPharma Dive)
Feb-13-24 07:48PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Feb-12-24 09:16AM	Gear Up for Alnylam (ALNY) Q4 Earnings: Wall Street Estimates for Key Metrics (Zacks)
Feb-08-24 10:00AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-05-24 05:02PM	Insider Sell: EVP, CLO & Secretary Indrani Franchini Sells 1,591 Shares of Alnylam ... (GuruFocus.com)
Jan-30-24 03:02PM	Baillie Gifford Adjusts Stake in Alnylam Pharmaceuticals (GuruFocus.com)
Jan-29-24 08:00AM	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results (Business Wire)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Greenstreet Yvonne	Chief Executive Officer	Aug 20 '24	Option Exercise	85.00	15,000	1,275,000	88,441	Aug 22 08:01 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 20 '24	Sale	280.00	15,000	4,200,000	73,441	Aug 22 08:01 PM
Greenstreet Yvonne	Officer	Aug 20 '24	Proposed Sale	280.00	15,000	4,200,000		Aug 20 05:10 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 12 '24	Option Exercise	89.09	20,725	1,846,429	34,906	Aug 14 04:12 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 12 '24	Sale	270.99	22,025	5,968,516	12,881	Aug 14 04:12 PM
Fitzgerald Kevin Joseph	Officer	Aug 12 '24	Proposed Sale	269.52	22,025	5,936,178		Aug 12 04:07 PM
Ausiello Dennis A	Director	Aug 06 '24	Option Exercise	119.68	20,250	2,423,452	20,386	Aug 08 04:10 PM
Ausiello Dennis A	Director	Aug 06 '24	Sale	262.00	20,250	5,305,586	136	Aug 08 04:10 PM
Ausiello Dennis A	Director	Aug 06 '24	Proposed Sale	266.66	20,250	5,399,865		Aug 06 04:07 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 01 '24	Option Exercise	85.00	15,148	1,287,580	88,589	Aug 02 08:01 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 01 '24	Sale	270.00	15,148	4,089,960	73,441	Aug 02 08:01 PM
Greenstreet Yvonne	Officer	Aug 01 '24	Proposed Sale	270.00	15,148	4,089,960		Aug 01 04:01 PM
Greenstreet Yvonne	Chief Executive Officer	Jul 11 '24	Sale	261.00	7,093	1,851,273	73,441	Jul 12 08:02 PM
SCHULMAN AMY W	Director	Jun 25 '24	Option Exercise	131.21	8,500	1,115,285	16,936	Jun 27 04:04 PM
SCHULMAN AMY W	Director	Jun 25 '24	Sale	240.00	8,500	2,040,000	8,436	Jun 27 04:04 PM
PYOTT DAVID E I	Director	Jun 24 '24	Option Exercise	80.76	32,450	2,620,611	32,586	Jun 26 04:28 PM
PYOTT DAVID E I	Director	Jun 24 '24	Sale	220.69	32,450	7,161,360	136	Jun 26 04:28 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jun 25 '24	Sale	230.99	2,103	485,773	15,609	Jun 26 04:28 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 25 '24	Sale	230.99	8,301	1,917,475	80,534	Jun 26 04:27 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Jun 25 '24	Sale	231.00	1,605	370,747	28,892	Jun 26 04:26 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Jun 25 '24	Sale	231.00	1,605	370,747	11,660	Jun 26 04:26 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jun 25 '24	Sale	230.99	1,198	276,731	14,181	Jun 26 04:26 PM
SCHULMAN AMY W	Director	May 29 '24	Option Exercise	66.83	30,000	2,004,900	30,136	May 31 07:00 PM
SCHULMAN AMY W	Director	May 29 '24	Sale	148.60	21,700	3,224,546	8,436	May 31 07:00 PM
SHARP PHILLIP A	Director	Feb 29 '24	Option Exercise	59.25	30,000	1,777,500	30,000	Mar 01 04:12 PM
SHARP PHILLIP A	Director	Feb 29 '24	Sale	151.34	30,000	4,540,071	0	Mar 01 04:12 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '24	Option Exercise	0.00	1,667	0	5,737	Feb 29 04:18 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 28 '24	Sale	155.30	501	77,805	5,236	Feb 29 04:18 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '24	Option Exercise	0.00	1,908	0	20,052	Feb 29 04:18 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 28 '24	Sale	155.30	574	89,145	19,478	Feb 29 04:18 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '24	Option Exercise	0.00	5,921	0	51,060	Feb 29 04:18 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 28 '24	Sale	155.31	2,932	455,357	48,128	Feb 29 04:18 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 27 '24	Option Exercise	0.00	1,908	0	9,240	Feb 29 04:17 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 28 '24	Sale	155.30	574	89,145	8,666	Feb 29 04:17 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 27 '24	Option Exercise	0.00	878	0	4,462	Feb 29 04:16 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 28 '24	Sale	155.30	329	51,094	4,133	Feb 29 04:16 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 16 '24	Sale	148.06	1,308	193,666	7,332	Feb 20 04:09 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 16 '24	Sale	148.06	1,007	149,099	18,144	Feb 20 04:08 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 16 '24	Sale	148.06	1,009	149,397	4,070	Feb 20 04:08 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 16 '24	Sale	148.06	7,030	1,040,885	45,139	Feb 20 04:07 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 01 '24	Option Exercise	0.00	5,175	0	5,175	Feb 05 04:05 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 02 '24	Sale	170.99	1,591	272,050	3,584	Feb 05 04:05 PM
BONNEY MICHAEL W	Director	Dec 27 '23	Option Exercise	96.45	30,000	2,893,500	46,029	Dec 29 04:03 PM
BONNEY MICHAEL W	Director	Dec 27 '23	Sale	195.00	30,000	5,850,000	16,029	Dec 29 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALNY

Alnylam Pharmaceuticals Inc

Upgrade your FINVIZ experience